Abstract Background Recurrent Clostridioides difficile infection, associated with dysbiosis of
gut microbiota, has substantial disease burden in the USA. RBX2660 is a live biotherapeutic …

Fatty liver disease is an emerging contributor to disease burden worldwide. The past
decades of work established the heterogeneous nature of non-alcoholic fatty liver disease …

Since the discovery of HIV-1, progress has been made in deciphering the viral replication
cycle and mechanisms of host–pathogen interactions that has facilitated the implementation …

Importance Dysbiosis has been robustly demonstrated in Parkinson disease (PD), and fecal
microbiota transplantation (FMT) has shown promising effects in preclinical PD models …

BACKGROUND Clostridioides difficile infection (CDI) remains a major public health threat in
the United States with an estimated 365,000 individuals being diagnosed annually, with …

Background Fecal microbiota, live-jslm (RBL; REBYOTA™), the first microbiota-based live
biotherapeutic approved by the US Food and Drug Administration to prevent recurrent …

Introduction Clostridioides difficile infection (CDI) is a major healthcare problem in the
developed world, and effective management of recurrent infection remains one of the …

A recently published manuscript described findings from a phase 2 open label study of the
microbiota-based live biotherapeutic product RBX2660 in patients with two or more previous …

Background: Microbiota restoration is highly effective to treat recurrent Clostridioides difficile
infection (CDI) in observational studies (cure rates> 90%) but efficacy in controlled clinical …

Background: RBL is the first microbiota-based live biotherapeutic approved by the US Food
and Drug Administration for the prevention of rCDI in adults after antibiotic treatment for …